Showing results (181-190 of 280) with videos related to
Sort By:
Pageof 28
Clinical Lymphoma, Myeloma & Leukemia|May 25, 2021
Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy BackboneAbhay Singh, Swapna Thota, Terrence Bradley, et al.Blood|April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson, Peter L Greenberg, John M Bennett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.Leukemia Research|December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Amanda Blackford, B Douglas Smith, et al.British Journal of Haematology|February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapySteven E Coutre, Megan Othus, Bayard Powell, et al.BMC Genomics|September 25, 2015
Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromesYan Guo, Amma Bosompem, Sanjay Mohan, et al.Leukemia Research|September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studiesKelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.Cancer Discovery|March 27, 2016
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid LeukemiaSara E Meyer, Tingting Qin, David E Muench, et al.Blood Advances|October 31, 2025
Decitabine-cedazuridine in patients with MDS and TP53 mutationsSamuel Urrutia, Koji Sasaki, Alex Bataller, et al.Pageof 28